SALT LAKE CITY, March 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Board of Directors has authorized a third $100 million stock repurchase program. In connection with this stock repurchase authorization, the Company has entered into an accelerated share repurchase (ASR) agreement with J.P. Morgan under which it will repurchase approximately $50 million of its common stock. During the past twelve months, the Company has returned $200 million to shareholders through the completion of its previously authorized stock repurchase programs.
